AstraZeneca featured four presentations in the presidential sessions of the European Society for Medical Oncology congress in Madrid. The selection highlights the breadth of its oncology portfolio. Susan Galbraith, head of AstraZeneca’s cancer research and development, told STAT that the conference demonstrates how the company’s cancer work is progressing. She noted that this progress involves both established medicines and new molecules. The presentations included highlights from a mix of old standbys and new drugs. These new agents could expand the company’s armament of medicines. The meeting also showcased new combinations of approved drugs. Additionally, it put a spotlight on what could be the company’s next targeted chemotherapy to reach the market.